Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Apr 14;3(3):208-211.
doi: 10.1016/j.jdcr.2017.02.015. eCollection 2017 May.

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma

Mathew R Birnbaum  1 , Michelle W Ma  1 , Sarah Fleisig  2 , Stuart Packer  2 , Bijal D Amin  3 , Mark Jacobson  3 , Beth N McLellan  1
Affiliations
Case Reports

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma

Mathew R Birnbaum et al. JAAD Case Rep. .
No abstract available

Keywords: CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death-1; PD-L, programmed cell death ligand; immune checkpoint inhibitors; immune-related adverse events; immunotherapy; irAE, immune-related adverse event; nivolumab; programmed cell death-1; sarcoidosis.

PubMed Disclaimer

Figures

Fig 1
Fig 1
A, Firm, erythematous papules and plaques on the glabella and periorbital area with spread to the nasal bridge. B, Scaly papules and plaques on the posterior neck. C, Nodular collections of epithelioid and multinucleated histiocytes surrounded by a sparse infiltrate of lymphocytes are present throughout the dermis. (Hematoxylin-eosin stain; original magnification: ×10.)
Fig 2
Fig 2
The pathogenesis of sarcoidosis and competing paradigms.
See this image and copyright information in PMC

References

    1. Opdivo (nivolumab) Prescribing Information, May 2016. Food and Drug Association Website. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125554s019lbl.pdf. (Updated May 10, 2016. Accessed September 12, 2016).
    1. Danlos F.X., Pagès C., Baroudjian B. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149(5):e133–e136. - PubMed
    1. Suozzi K.C., Stahl M., Ko C.J. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016;2(3):264–268. - PMC - PubMed
    1. Montaudié H., Pradelli J., Passeron T., Lacour J.-P., Leroy S. Pulmonary sarcoid-like granulomatosis induced by nivolumab [e-pub ahead of print] Br J Dermatol. 2016 - PubMed
    1. Keir M.E., Liang S.C., Guleria L. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895. - PMC - PubMed

Publication types

LinkOut - more resources